Novogen (NASDAQ:KZIA) Shares Down 1.9% – Here’s What Happened

Novogen Limited (NASDAQ:KZIA)’s share price fell 1.9% on Friday . The company traded as low as $5.95 and last traded at $6.14. 116,269 shares traded hands during trading, a decline of 49% from the average session volume of 225,823 shares. The stock had previously closed at $6.26.

Analysts Set New Price Targets

KZIA has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Novogen in a research report on Thursday, January 22nd. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Novogen in a research report on Wednesday, January 28th. Finally, Wall Street Zen upgraded Novogen to a “hold” rating in a research note on Saturday, November 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Novogen has a consensus rating of “Hold” and a consensus target price of $19.00.

Novogen Price Performance

The firm’s 50-day moving average is $6.87 and its 200-day moving average is $7.76.

Novogen (NASDAQ:KZIA) last issued its quarterly earnings results on Friday, November 7th. The company reported ($6.14) EPS for the quarter. The business had revenue of $0.59 million for the quarter.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.